日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients

对 142 例未经治疗的多发性骨髓瘤患者进行临床导向的变异筛查和拷贝数检测的基因组测序

Kortuem, K M; Braggio, E; Bruins, L; Barrio, S; Shi, C S; Zhu, Y X; Tibes, R; Viswanatha, D; Votruba, P; Ahmann, G; Fonseca, R; Jedlowski, P; Schlam, I; Kumar, S; Bergsagel, P L; Stewart, A K

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.

ficlatuzumab 单药治疗或与厄洛替尼联合治疗难治性晚期实体瘤和多发性骨髓瘤的 I 期临床试验

Patnaik A, Weiss G J, Papadopoulos K P, Hofmeister C C, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo F C, Cotreau M M, Ramanathan R K